scholarly journals Efficacy and Tolerability of Fitostimoline in Two Different Forms (Soaked Gauzes and Cream) and Citrizan Gel in the Topical Treatment of Second-Degree Superficial Cutaneous Burns

2011 ◽  
Vol 2011 ◽  
pp. 1-8 ◽  
Author(s):  
Patrizia Martini ◽  
Carlo Mazzatenta ◽  
Giorgio Saponati
Keyword(s):  
Adverse Effects ◽  
Aqueous Extract ◽  
Topical Application ◽  
Topical Treatment ◽  
Transverse Diameter ◽  
Triticum Vulgare ◽  
Thermal Origin ◽  
Pain At Rest ◽  
To Receive ◽  
Second Degree

A total of 227 patients (mean age 41.3 years, 52% females) with at least one second-degree superficial cutaneous burn of thermal origin of a smallest transverse diameter ≥20 mm and a largest transverse diameter ≤90 mm were randomised to receive the topical application of aqueous extract ofTriticum vulgare(Fitostimoline) in two different forms (soaked gauzes and cream) or catalase of horse origin in form of gel (Citrizan Gel), given up to healing or to a maximum of 20 days. The rate of lesion healing at end of study was significantly higher in patients treated with Fitostimoline (gauzes 97.3%, cream 91.5%) than in those receiving catalase (84.5%). The pooled Fitostimoline groups were also significantly more effective than catalase gel in reducing total symptoms score, pain at medication, pain at rest, and burning at end of study. Both formulations of Fitostimoline and catalase gel were well tolerated in terms of adverse effects in the site of application.

scholarly journals Nitroglycerin in Dermatology

2020 ◽  
Vol 71 (7) ◽  
pp. 497-503
Author(s):  
Mihaela Paula Toader ◽  
Madalina Mocanu ◽  
Roxana Irina Iancu ◽  
Stefan Toader ◽  
Virgil Bulimar ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Blood Vessels ◽  
Topical Application ◽  
Alopecia Areata ◽  
Topical Treatment ◽  
Therapeutic Potential ◽  
Arterial Blood ◽  
Ischemic Diseases

Nitroglycerin has traditionally been used in medicine for over 130 years for its potent dilator effect on both venous and arterial blood vessels. Cardiovascular ischemic diseases are among the classic indications. However, the possibility to incorporate nitroglycerin in different galenic forms renders it new therapeutic potential through topical application, both in surgery and in dermatology (Raynaud syndrome, chondrodermatitis, pernio erythema, alopecia areata, ulcers of different etiologies). Nitroglycerin is used for topical treatment as 0.5%, 1% or 2% ointment, lower concentrations limiting the probability of systemic adverse effects occurence.

scholarly journals Efficacy and Tolerability of Clarema 1% Cream and Hirudoid 40000 U.APTT Gel in the Topical Treatment of Haematomas and/or Subcutaneous Haematic Extravasations

2012 ◽  
Vol 2012 ◽  
pp. 1-5
Author(s):  
Tiziana Polieri ◽  
Enrico Orsoni ◽  
Giorgio Saponati ◽  
Enrico Castellacci
Keyword(s):  
Heparan Sulfate ◽  
Topical Treatment ◽  
Local Treatment ◽  
Signs And Symptoms ◽  
End Point ◽  
Baseline Visit ◽  
Pain At Rest ◽  
To Receive

Ninety-six caucasian both-gender patients with haematomas and/or subcutaneous haematic extravasation of traumatic or surgical origin were randomized to receive local treatment (max 10 days) with heparan sulfate cream or glycosaminoglycan-polysulphate (GAGPS) gel. Signs (oedema, disability, and colour of the lesion) and symptoms (pain at rest and at movement) (scored 0–3), the sum of the scores (primary end point), and the size of the lesion were evaluated at the baseline visit and afterwards every 5 days. The rate of the patients completely healed at the end of the study was also recorded. The results of the study showed that heparan sulfate 1% cream was comparable or superior to GAGPS gel in relieving signs and symptoms. No AEs were recorded.

scholarly journals Pulsed Shortwave Therapy in Cervical Osteoarthritis: an NSAID- Controlled, Randomized Clinical Trial

2021 ◽  
Author(s):  
A. Rachid El Mohammad ◽  
Sree Koneru ◽  
Richard Staelin ◽  
Kenneth McLeod ◽  
Omar Tabbouche ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Outcome Measures ◽  
Neck Disability Index ◽  
Primary Outcome Measure ◽  
Pain Medication ◽  
Secondary Outcome ◽  
Pain Duration ◽  
Cox 2 ◽  
Neck Disability ◽  
Pain At Rest

AbstractAssess treatment superiority of pulsed shortwave therapy (PSWT) against COX-2 NSAID therapy, in reducing disability and pain due to cervical osteoarthritis. Two hundred chronic pain suffers (average pain duration about 2 years) diagnosed with cervical osteoarthritis by radiological imaging were randomized into one of two treatment arms: COX-2 NSAID treatment; etoricoxib 60 mg/day for 4 weeks; or PSWT treatment worn 24 h/day for 4 weeks. The primary outcome measure was the 4-week score on the Neck Disability Index (NDI), a 10-question assessment on a 50-point scale. Secondary outcome measures included pain (at rest and during activity) measured on a visual analog scale (VAS) of 0–100 mm, dose count of rescue pain medication (paracetamol) use, and a treatment satisfaction rating. These 4-week scores were compared across the two arms to assess superiority. After 4 weeks of treatment, subjects in both study arms reported statistically significant (p < 0.0001) reductions in NDI, with final scores of 11.24-NSAID and 9.34-PSWT, VASrest, with final scores of 30.08-NSAID; 22.76-PSWT, and VASactivity, with final scores of 36.40-NSAID; 27.42-PSWT. The absolute reduction from baseline in NDI was significantly greater in the PSWT arm than NSAID arm (3.66 points; 95% CI 2.3 to 5.02; p < 0.0001). Similarly, the reductions from baseline in VASrest and VASactivity were significantly greater in the PSWT arm than NSAID arm (10.89 mm; 95% CI 6.90 to 14.87; p < 0.0001; and 12.05 mm; 95% CI 7.76 to 16.33; p < 0.0001, respectively). The PSWT arm used 50% less rescue pain medication. Eleven adverse effects were reported in the NSAID arm and zero in the PSWT arm. Both NSAID and PSWT treatments resulted in statistically significant improvements in quality of life (NDI) and reduction in pain (VAS) resulting from cervical osteoarthritis. However, the PSWT intervention showed superior improvements in all outcome measures when compared to the NSAID arm with no adverse effects. Clinicaltrials.gov (NCT03542955).

Effectiveness of Triamcinolone Hexacetonide Intraarticular Injection in Interphalangeal Joints: A 12-week Randomized Controlled Trial in Patients with Hand Osteoarthritis

2015 ◽  
Vol 42 (10) ◽  
pp. 1869-1877 ◽  
Author(s):  
Natalia de Oliva Spolidoro Paschoal ◽  
Jamil Natour ◽  
Flavia S. Machado ◽  
Hilda Alcântara Veiga de Oliveira ◽  
Rita Nely Vilar Furtado
Keyword(s):  
Adverse Effects ◽  
Repeated Measures ◽  
Controlled Trial ◽  
Hand Function ◽  
Intraarticular Injection ◽  
Pinch Strength ◽  
Hand Osteoarthritis ◽  
Triamcinolone Hexacetonide ◽  
Link Type ◽  
Pain At Rest

Objective.To evaluate the effectiveness and tolerance of intraarticular injection (IAI) of triamcinolone hexacetonide (TH) for the treatment of osteoarthritis (OA) of hand interphalangeal (IP) joints.Methods.Sixty patients who underwent IAI at the most symptomatic IP joint were randomly assigned to receive TH/lidocaine (LD; n = 30) with TH 20 mg/ml and LD 2%, or just LD (n = 30). The injected joint was immobilized with a splint for 48 h in both groups. Patients were assessed at baseline and at 1, 4, 8, and 12 weeks by a blinded observer. The following variables were assessed: pain at rest [visual analog scale (VAS)r], pain at movement (VASm), swelling (physician VASs), goniometry, grip and pinch strength, hand function, treatment improvement, daily requirement of paracetamol, and local adverse effects. The proposed treatment (IAI with TH/LD) was successful if statistical improvement (p < 0.05) was achieved in at least 2 of 3 VAS. Repeated-measures ANOVA test was used to analyze intervention response.Results.Fifty-eight patients (96.67%) were women, and the mean age was 60.7 years (± 8.2). The TH/LD group showed greater improvement than the LD group for VASm (p = 0.014) and physician VASs (p = 0.022) from the first week until the end of the study. In other variables, there was no statistical difference between groups. No significant adverse effects were observed.Conclusion.The IAI with TH/LD has been shown to be more effective than the IAI with LD for pain on movement and joint swelling in patients with OA of the IP joints. Regarding pain at rest, there was no difference between groups. Trial registration number: ClinicalTrials.gov (NCT02102620).

scholarly journals Reaction or infection: topical chloramphenicol treatment

2013 ◽  
Vol 95 (1) ◽  
pp. e20-e21 ◽  
Author(s):  
RJ Livingston ◽  
JW Butterworth ◽  
P Belt
Keyword(s):  
Topical Application ◽  
Topical Treatment ◽  
Delayed Hypersensitivity ◽  
Delayed Reaction

Chloramphenicol is a topical treatment that is used widely, especially in wounds around the eyes. In our practice there have been a number of cases of delayed hypersensitivity to chloramphenicol that has been mismanaged initially as an infective cellulitis. We hope to share some of our experience of this uncommon reaction to highlight the delayed reaction that can occur with topical application of this drug.

scholarly journals Enhanced Transdermal Delivery of Pranoprofen Using a Thermo-Reversible Hydrogel Loaded with Lipid Nanocarriers for the Treatment of Local Inflammation

2021 ◽  
Vol 15 (1) ◽  
pp. 22
Author(s):  
María Rincón ◽  
Marcelle Silva-Abreu ◽  
Lupe Carolina Espinoza ◽  
Lilian Sosa ◽  
Ana Cristina Calpena ◽  
...  
Keyword(s):  
Human Skin ◽  
Topical Application ◽  
Topical Treatment ◽  
Transdermal Delivery ◽  
Ex Vivo ◽  
Skin Permeation ◽  
In Vitro Release ◽  
Heterogeneous Structure ◽  
Clinical Environment ◽  
Local Skin

A biocompatible topical thermo-reversible hydrogel containing Pranoprofen (PF)-loaded nanostructured lipid carriers (NLCs) was studied as an innovative strategy for the topical treatment of skin inflammatory diseases. The PF-NLCs-F127 hydrogel was characterized physiochemically and short-time stability tests were carried out over 60 days. In vitro release and ex vivo human skin permeation studies were carried out in Franz diffusion cells. In addition, a cytotoxicity assay was studied using the HaCat cell line and in vivo tolerance study was performed in humans by evaluating the biomechanical properties. The anti-inflammatory effect of the PF-NLCs-F127 was evaluated in adult male Sprague Daw-ley® rats using a model of inflammation induced by the topical application of xylol for 1 h. The developed PF-NLCs-F127 exhibited a heterogeneous structure with spherical PF-NLCs in the hydrogel. Furthermore, a thermo-reversible behaviour was determined with a gelling temperature of 32.5 °C, being close to human cutaneous temperature and thus favouring the retention of PF. Furthermore, in the ex vivo study, the amount of PF retained and detected in human skin was high and no systemic effects were observed. The hydrogel was found to be non-cytotoxic, showing cell viability of around 95%. The PF-NLCs-F127 is shown to be well tolerated and no signs of irritancy or alterations of the skin’s biophysical properties were detected. The topical application of PF-NLCs-F127 hydrogel was shown to be efficient in an inflammatory animal model, preventing the loss of stratum corneum and reducing the presence of leukocyte infiltration. The results from this study confirm that the developed hydrogel is a suitable drug delivery carrier for the transdermal delivery of PF, improving its dermal retention, opening the possibility of using it as a promising candidate and safer alternative to topical treatment for local skin inflammation and indicating that it could be useful in the clinical environment.

Pirenzepine in Non-Ulcer Dyspepsia: A Double-Blind Multicentre Trial

1990 ◽  
Vol 18 (1) ◽  
pp. 16-20 ◽  
Author(s):  
P.M. Smith ◽  
A.H. Troughton ◽  
F. Gleeson ◽  
J. Walters ◽  
C.F. McCarthy
Keyword(s):  
Abdominal Pain ◽  
Placebo Group ◽  
Adverse Effects ◽  
Multicentre Study ◽  
Multicentre Trial ◽  
Nausea And Vomiting ◽  
Double Blind ◽  
Non Ulcer Dyspepsia ◽  
Upper Abdominal ◽  
To Receive

In a double-blind multicentre study to compare pirenzepine with placebo in non-ulcer dyspepsia, 71 patients were randomized to receive 50 mg pirenzepine or placebo given orally twice daily for 4 weeks. The trial was not completed by five patients in the pirenzepine group and six in the placebo group. There were no significant differences between the groups in respect to changes in total symptoms (upper abdominal pain, nausea and vomiting, early satiety and postprandial bloating, eructation and pyrosis) scores and outcome, although 27/35 (77%) patients receiving pirenzepine were cured or improved compared with 22/36 (61%) receiving the placebo. Adverse effects were reported by 13 (37%) patients treated with pirenzepine and by six (17%) treated with placebo, seven withdrawing due to adverse effects.

Emulsion incorporating Eugenia dysenterica aqueous extract entrapped in chitosan microparticles as a novel topical treatment of cutaneous infections

2020 ◽  
Vol 55 ◽  
pp. 101372 ◽  
Author(s):  
Sandra M. Mazutti da Silva ◽  
Ricardo Ferreira-Nunes ◽  
Clara R. Amore ◽  
Diegue H.N. Martins ◽  
Aline Pic-Taylor ◽  
...  
Keyword(s):  
Aqueous Extract ◽  
Topical Treatment ◽  
Cutaneous Infections ◽  
Chitosan Microparticles ◽  
Eugenia Dysenterica

scholarly journals Understanding American Indian Perceptions Toward Radiation Therapy

2020 ◽  
Vol 27 (3) ◽  
pp. 107327482094599
Author(s):  
Samir H. Patel ◽  
Sasha Ebrahimi ◽  
Donald W. Northfelt ◽  
Timothy E. Mathews ◽  
Farhia M. Omar ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Adverse Effects ◽  
American Indian ◽  
Alaska Native ◽  
Medical Center ◽  
Transportation Cost ◽  
Survey Study ◽  
Cost Of Treatment ◽  
Patients With Cancer ◽  
To Receive

Many American Indian (AI) and Alaska native (AN) patients do not complete guideline-concordant cancer care for the 4 most common cancers. Our aim was to better understand AI/AN attitudes toward radiation therapy (RT). Patients eligible for this survey study were AI/AN patients with cancer at the Phoenix Indian Medical Center who either received previous RT or were recommended to receive RT. An 18-item questionnaire was administered to each of the 50 participants from October 1, 2018, through February 15, 2019. Willingness to travel for RT was compared to respondent characteristics, concerns regarding RT, and obstacles to obtain RT. Duration of RT was important to 78% of patients: 24% would consider traveling 25 miles or more for a standard course, and 48% would travel that distance for a shorter course ( P < .001). The top-ranked barriers to RT were transportation, cost of treatment, and insurance compatibility. The top-ranked concerns about RT were adverse effects, cost of treatment, and fear of RT. Concerns about adverse effects were associated with the radiation team’s inability to explain the treatment ( P = .05). Transportation concerns were significantly associated with accessibility ( P = .02), communication with the RT team ( P = .02), and fear of RT ( P = .04). AI/AN patients are concerned about the adverse effects of RT and the logistics of treatment, particularly costs, transportation, and insurance compatibility. Use of culturally specific education and hypofractionation regimens may increase acceptance of RT for AI/AN patients with cancer, and this hypothesis will be tested in a future educational intervention-based study.

Sign in / Sign up

Export Citation Format

Share Document